US Supreme Court denies Vanda's bid to revive sleep drug patents

Vanda denied opportunity to revive patents for its sleep-disorder drug in dispute against Teva | Decision also rejects revisiting the 2007 case, KSR International v Teleflex, concerning the issue of obviousness in patent claims.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com

More on this story

Biotech

Regeneron and Amgen call a truce on two Eylea biosimilar patents

28 October 2026 Both companies have agreed to dismiss claims and counterclaims involving Amgen’s 2 mg aflibercept biosimilar, while their wider feud continues.

Biotech

10x and Parse set to end sequencing feud after appeals court defeat

23 October 2026 Following the Federal Circuit’s decision to uphold the invalidation of three patents, the parties are set to drop their remaining claims, despite 10x’s separate multi-million dollar jury win.

Biotech

Guardant loses second patent challenge to TwinStrand amid $245m damages fallout

16 October 2026 All 30 claims of a key DNA sequencing patent have been upheld for a second time, marking another setback in a long-running dispute that has already left Guardant facing a $245 million bill.

More features

Regeneron and Amgen call a truce on two Eylea biosimilar patents

HeartFlow targets AI cardiac imaging rival over patents and trade secrets

Womble Bond Dickinson loses trio of partners to US rival

‘Companies that don’t leverage AI will struggle to keep up’: Umicore IP chief

Mewburn Ellis hires first CTO to boost investment in AI and digital innovation

10x and Parse set to end sequencing feud after appeals court defeat

Dr Reddy’s eyes appeal stakes as Boehringer hearing ends

Amarin and Hikma call time on six-year skinny label fight

US Supreme Court denies Vanda's bid to revive sleep drug patents

More on this story

Editor's picks

Editor's picks

More features